BioNTech SE - American Depositary Shares (BNTX) Covered Calls

You can sell covered calls on BioNTech SE - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BNTX (prices last updated Fri 4:16 PM ET):

BioNTech SE - American Depositary Shares (BNTX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
99.72 -3.84 97.00 101.95 3.4M - 0.0
Covered Calls For BioNTech SE - American Depositary Shares (BNTX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Dec 20 100 4.50 97.45 2.6% 26.4%
Jan 17 100 7.10 94.85 5.4% 30.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.